The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells.
Bouvardin is an antitumor drug that inhibits protein synthesis in intact eukaryotic cells and cell-free systems. Our present studies have shown that bouvardin acts at the level of the 80 S ribosome in a site somehow involved with the interaction of EF1 and EF2. Indeed bouvardin inhibits EF1-dependent binding of aminoacyl-tRNA and EF2-dependent translocation of peptidyl-tRNA but does not affect the nonenzymic translocation since this reaction does not require EF2. The site of the 80 S ribosome involved in the interaction with bouvardin appears to be independent from the cycloheximide and the cryptopleurine binding sites since yeast mutants resistant to cycloheximide or cryptopleurine are sensitive to bouvardin.
D000970:Antineoplastic Agents; D002474:Cell-Free System; D003513:Cycloheximide / Q000494:pharmacology; D005057:Eukaryotic Cells; D010445:Peptide Elongation Factors / Q000378:metabolism*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010458:Peptidyl Transferases / Q000378:metabolism; D010649:Phenylalanine / Q000378:metabolism; D014176:Protein Biosynthesis; D012346:RNA, Transfer, Amino Acyl / Q000378:metabolism; D012270:Ribosomes / Q000378:metabolism
D000970:Antineoplastic Agents; D010445:Peptide Elongation Factors; D010456:Peptides, Cyclic; D012346:RNA, Transfer, Amino Acyl; C018234:bouvardin; D010649:Phenylalanine; D003513:Cycloheximide; D010458:Peptidyl Transferases